AR050631A1 - Combinacion de compuestos organicos - Google Patents

Combinacion de compuestos organicos

Info

Publication number
AR050631A1
AR050631A1 ARP050103737A ARP050103737A AR050631A1 AR 050631 A1 AR050631 A1 AR 050631A1 AR P050103737 A ARP050103737 A AR P050103737A AR P050103737 A ARP050103737 A AR P050103737A AR 050631 A1 AR050631 A1 AR 050631A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
diseases
inhibitors
pharmaceutically acceptable
patients
Prior art date
Application number
ARP050103737A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35385557&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR050631(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR050631A1 publication Critical patent/AR050631A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)

Abstract

Composicion farmacéutica, comprende un agonista PPAR, o sales farmacéuticamente aceptable del mismo, solos o en combinacion con por lo menos un ingrediente activo seleccionado del grupo que consiste de: i) compuestos con HDL en incremento; ii) antidiabélicos; iii) un agente antihipertensivo; iv) un modulador de absorcion de colesterol; v) análogos y miméticos apo-A1; vi) inhibidores de renina; vii) inhibidores de trombina; viii) inhibidores de aldosterona; ix) agonistas GLP-1; x) antagonistas del receptor de glucagon; xi) agonistas del receptor 1 de canabinoide; xii) agentes antiobesidad; y xiii) inhibidores de la agregacion de plaquetas; o, en cada caso, una sal farmacéuticamente aceptable del mismo; y opcionalmente un portador farmacéuticamente aceptable. La composicion farmacéutica se puede emplear para el tratamiento de adiciones (por ejemplo, nicotina y cocaína), dislipidemia, hiperlipidemia, hipercolesterolemia, ateroesclerosis, hipertrigliceridemia, falla cardíaca, infarto al miocardio, enfermedades vasculares, enfermedades cardiovasculares, choque, claudicacion intermitente, restenosis después de PCTA, hipertension, obesidad incluyendo reduccion del riesgo CV en pacientes obesos, inflamacion, artritis, cáncer incluyendo cáncer de pecho, colon y prostata, enfermedad de Alzheimer, trastornos de la piel, enfermedades respiratorias, trastornos oftálmicos, IBDs (enfermedad del intestino irritable), enfermedad de Crohn, hipofibrinolisis, estado hipercoagulable, síndrome metabolico/cardiometabolico, CRP elevado, aparacion de microalbuminuria, reduccion de proteinuria, falla renal (DM, no DM), grasa en el hígado no alcoholico NASH (hepatitis de estado no alcoholico), eventos CV en pacientes con un CRP alto, demencia vascular, psoriasis, dano por reperfusion de isquemia, asma, COPD, eosinofilia, RA, hipersensibilidad en las vías aéreas (AHR), enfermedades digestivas inflamatorias (por ejemplo, colitis ulcerativas), enfermedades de respuestas inflamatorias inducidas por antígeno. Los compuestos de la presente son particularmente utiles en mamíferos como agentes hipoglicémicos para el tratamiento y prevencion de condiciones tales como tolerancia a glucosa danada, hiperglicemia, resistencia a insulina, diabetes de tipo 1 y de tipo 2, y Síndrome X. También se contempla la administracion de las combinaciones de la presente para el mejoramiento de metabolismo cardíaco y cardioproteccion en pacientes con trasplante de corazon, para facilitar el cese o reduccion de fumar y para prevenir o tratar condiciones asociadas con el fumar. Reivindicacion 4: La composicion farmacéutica de acuerdo con la reivindicacion 3, en donde el agonista alfa/gama PPAR dual es de la formula (1). Reivindicacion 5: La composicion farmacéutica de acuerdo con la reivindicacion 3, en donde el agonista alfa/gama PPAR dual es 3-isobutil-8-(6-metoxi-isoquinolin-4-ilmetil)-1-metil-3,7-dihidro-purina-2,6-diona.
ARP050103737A 2004-09-09 2005-09-07 Combinacion de compuestos organicos AR050631A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60831004P 2004-09-09 2004-09-09
US60957704P 2004-09-14 2004-09-14
US68973805P 2005-06-10 2005-06-10

Publications (1)

Publication Number Publication Date
AR050631A1 true AR050631A1 (es) 2006-11-08

Family

ID=35385557

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050103737A AR050631A1 (es) 2004-09-09 2005-09-07 Combinacion de compuestos organicos

Country Status (13)

Country Link
US (1) US20070299047A1 (es)
EP (1) EP1791600A1 (es)
JP (1) JP2008512486A (es)
KR (1) KR20070106677A (es)
AR (1) AR050631A1 (es)
AU (1) AU2005282290B2 (es)
BR (1) BRPI0515185A (es)
CA (1) CA2578290A1 (es)
GT (1) GT200500246A (es)
MX (1) MX2007002879A (es)
PE (1) PE20060594A1 (es)
TW (1) TW200621220A (es)
WO (1) WO2006029349A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE521512C2 (sv) 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
WO2004056363A2 (en) 2002-12-20 2004-07-08 Niconovum Ab A physically and chemically stable nicotine-containing particulate material
CA2646942C (en) 2006-03-16 2014-07-29 Niconovum Ab Improved snuff composition
EP1972335A1 (en) * 2007-03-23 2008-09-24 Krka Solid dosage forms comprising aliskiren and pharmaceutically acceptable salts thereof
AU2013201887B2 (en) * 2007-04-11 2016-02-25 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
CN105250285B (zh) * 2007-04-11 2019-09-06 奥默罗斯公司 预防和治疗成瘾的组合物和方法
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
IE20070928A1 (en) * 2007-12-21 2009-09-30 Giuliani Int Ltd Multi target ligands
US9408837B2 (en) * 2008-05-28 2016-08-09 Kitov Pharmaceutical Ltd. Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs
JPWO2009154230A1 (ja) * 2008-06-17 2011-12-01 持田製薬株式会社 非アルコール性脂肪肝炎の予防／改善・治療薬
PT2396081T (pt) 2009-02-16 2017-07-11 Nogra Pharma Ltd Compostos alquilamido e suas utilizações
BRPI1009141A2 (pt) 2009-03-11 2016-03-08 Omeros Corp composições e métodos para profilaxia e tratamento de vícios
CA2821985C (en) 2011-01-11 2019-07-09 Dimerix Bioscience Pty Ltd Combination therapy
WO2013071077A1 (en) * 2011-11-09 2013-05-16 Cornell University The use of pan-ppar agonists for prevention and treatment of huntington's disease and tauopathies
CA2864059C (en) 2012-02-09 2020-04-28 Nogra Pharma Limited Methods of treating fibrosis
WO2020030843A2 (es) * 2018-08-10 2020-02-13 Servicio Andaluz De Salud Agentes para el tratamiento del trastorno por uso de alcohol
EA202192207A1 (ru) 2019-02-08 2021-10-27 Ногра Фарма Лимитед Способ получения 3-(4'-аминофенил)-2-метоксипропионовой кислоты и ее аналогов и промежуточных соединений
EP4255427A1 (en) 2020-12-03 2023-10-11 Delta 4 GmbH Clopidogrel for use in the treatment of focal segmental glomerulosclerosis (fsgs)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3800038A (en) * 1972-04-21 1974-03-26 Biolog Concepts Inc Uterine administraton of eutectic solid solutions of steroid hormones in a steroidal lipid carrier
FR2530247B1 (fr) * 1982-07-13 1986-05-16 Sanofi Sa Nouveaux derives de la thieno (3, 2-c) pyridine, leur procede de preparation et leur application therapeutique
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
TW541316B (en) * 1995-12-21 2003-07-11 Astrazeneca Ab Prodrugs of thrombin inhibitors
US6488961B1 (en) * 1996-09-20 2002-12-03 Ethypharm, Inc. Effervescent granules and methods for their preparation
US6071539A (en) * 1996-09-20 2000-06-06 Ethypharm, Sa Effervescent granules and methods for their preparation
US7019010B2 (en) * 2001-09-27 2006-03-28 Novertis Ag Combinations
TW200303742A (en) * 2001-11-21 2003-09-16 Novartis Ag Organic compounds
PE20050157A1 (es) * 2003-05-20 2005-05-17 Novartis Ag Derivados de n-acil nitrogeno heterociclicos como ligandos del receptor activador del proliferador de peroxisoma (ppar)

Also Published As

Publication number Publication date
GT200500246A (es) 2006-04-17
EP1791600A1 (en) 2007-06-06
WO2006029349A1 (en) 2006-03-16
MX2007002879A (es) 2007-04-23
AU2005282290B2 (en) 2009-06-25
PE20060594A1 (es) 2006-08-18
US20070299047A1 (en) 2007-12-27
TW200621220A (en) 2006-07-01
JP2008512486A (ja) 2008-04-24
BRPI0515185A (pt) 2008-07-22
AU2005282290A1 (en) 2006-03-16
KR20070106677A (ko) 2007-11-05
CA2578290A1 (en) 2006-03-16

Similar Documents

Publication Publication Date Title
AR050631A1 (es) Combinacion de compuestos organicos
CN104302634B (zh) 用于抑制abl1、abl2和bcr‑abl1的活性的苯甲酰胺衍生物
KR101607081B1 (ko) 디피피-4 저해약과 다른 당뇨병 치료약과의 병용 또는 조합으로 이루어지는 의약
US20130030000A1 (en) Pharmaceutical compositions for the treatment of pain and other indications
US20230227441A1 (en) 2-oxo-oxazolidine-5-carboxamides as nav1.8 inhibitors
ES2902073T3 (es) Beta-hidroxietilaminas sustituidas con heteroarilo para uso en el tratamiento de hiperglucemia
US8592458B2 (en) Alpha7 nicotinic receptor selective ligands
KR20130130815A (ko) Gpr119 수용체 작용제로서 이환형 헤테로아릴 화합물
JP2021526123A (ja) オートタキシン阻害剤とその使用
EA024207B1 (ru) Пиразольные соединения
CN102898400B (zh) Gpr119激动剂及其应用
CN105377857A (zh) 新颖氮杂苯并咪唑衍生物
JP2023532998A (ja) 新規細胞代謝調節化合物およびそのウイルス性疾患の治療のための使用
KR101374412B1 (ko) 케모카인 수용체 조절제로서의 3-아미노시클로펜탄카르복스아미드
US20150259349A1 (en) Means and Method for Treating Solid Tumors
ES2199561T3 (es) Derivados de azatriciclo(3.3.1.1)decano y composiciones farmaceuticas que los contienen.
JPWO2021219019A5 (es)
CN101237866A (zh) 噻唑类衍生物和类似物在游离脂肪酸引起的疾病中的应用
AU2012254057B2 (en) Use of A2B adenosine receptor antagonists for treating heart failure and arrhythmia in post-myocardial infarction patients
US9649294B2 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
CN102317265B (zh) 用于治疗炎性疾病的2,4-嘧啶二胺化合物
KR20140000531A (ko) 이중환 구조를 갖는 신규한 ｇｐｃｒ 효능제
CA3018115A1 (en) Indolizine derivatives, composition and methods of use
CN104926706B (zh) 六氢并环戊二烯衍生物的盐及其制备方法和应用
US20230210837A1 (en) Novel cell metabolism modulating compounds and uses thereof for the treatment of viral diseases

Legal Events

Date Code Title Description
FB Suspension of granting procedure